Anti-obesity drug discovery: advances and challenges
Groups that started at 2mg and escalated gradually reported fewer and milder GI side effects than groups that started at 4mg, even when both reached the same final dose
Comparing adverse-event percentages from separate Wegovy and Zepbound trials can be misleading because study populations, doses, and reporting methods differ
of Med+ members given the GLP-1 Success Program say it helped minimize side effects* increase in quality of life was experienced by Med+ members given the GLP-1 Success Program** weight loss among WW Med+ members given the GLP-1 Success Program, on average, after 6 months*** *Based on survey responses of 166 participants in a 6-month clinical trial who had overweight or obesity, and were taking semaglutide/tirzepatide for weight loss within the WW Clinic Program and participating in the GLP-1 companion nutrition program
Compare the two in our retatrutide vs
Caren Mangarelli, pediatric expert and medical director of Lurie Children's Wellness and Weight Management Program, explains what parents need to know about GLP-1 medications for adolescents
